{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:35:09Z","timestamp":1784309709438,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40273-017-0579-0","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T02:22:26Z","timestamp":1510626146000},"page":"161-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8921-515X","authenticated-orcid":false,"given":"Livia Lovato Pires de","family":"Lemos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-0577","authenticated-orcid":false,"given":"Augusto Afonso","family":"Guerra J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2174-6800","authenticated-orcid":false,"given":"Marisa","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0210-4877","authenticated-orcid":false,"given":"Carlos","family":"Magliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2769-4615","authenticated-orcid":false,"given":"Isabela","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-4794","authenticated-orcid":false,"given":"Kathiaja","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7874-3398","authenticated-orcid":false,"given":"Ramon Gon\u00e7alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0210-0721","authenticated-orcid":false,"given":"Juliana","family":"Alvares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Godman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4046-629X","authenticated-orcid":false,"given":"Marion","family":"Bennie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7757-7519","authenticated-orcid":false,"given":"Ivan Ricardo","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e2nia Crisitna Canuto","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarice Alegre","family":"Pretramale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5880-5261","authenticated-orcid":false,"given":"Francisco de Assis","family":"Acurcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"579_CR1","unstructured":"Atos do Poder Legislativo, Rep\u00fablica Federativa do Brasil. Lei No 12.401, de 28 de abril de 2011. Di\u00e1rio Oficial da Uni\u00e3o. Bras\u00edlia, DF: Imprensa Nacional; 2011. p. 1\u20132."},{"issue":"2","key":"579_CR2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1017\/S0266462317000277","volume":"33","author":"MA Maloney","year":"2017","unstructured":"Maloney MA, Schwartz L, O\u2019Reilly D, Levine M. Drug disinvestment frameworks: components, challenges, and solutions. Int J Technol Assess Health Care. 2017;33(2):261\u20139.","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"579_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1017\/S0266462317000514","volume":"33","author":"M Orso","year":"2017","unstructured":"Orso M, de Waure C, Abraha I, Nicastro C, Cozzolino F, Eusebi P, et al. Health technology disinvestment worldwide: overview of programs and possible determinants. Int J Technol Assess Health Care. 2017;33(2):239\u201350.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"579_CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13012-017-0585-9","volume":"12","author":"J Brett","year":"2017","unstructured":"Brett J, Elshaug AG, Bhatia RS, Chalmers K, Badgery-Parker T, Pearson S-A. A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study. Implement Sci. 2017;12(1):58.","journal-title":"Implement Sci"},{"key":"579_CR5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40273-015-0293-8","volume":"33","author":"B Parkinson","year":"2015","unstructured":"Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S, et al. Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. Pharmacoeconomics. 2015;33:905\u201324.","journal-title":"Pharmacoeconomics"},{"key":"579_CR6","unstructured":"Casa Civil da Rep\u00fablica Federativa do Brasil. Decreto no 7.646, de 21 de dezembro de 2011. Di\u00e1rio Oficial da Uni\u00e3o. Bras\u00edlia, DF: Imprensa Nacional; 2011. p. 3\u20135."},{"issue":"2","key":"579_CR7","first-page":"279-28","volume":"33","author":"AA Guerra-J\u00fanior","year":"2017","unstructured":"Guerra-J\u00fanior AA, Lemos L, Godman B, Bennie M, Osorio de Castro C, Alvares J, et al. Health technology performance assessment: real-world evidence for public healthcare sustainability. Int J Technol Assess Health Care. 2017;33(2):279-28.","journal-title":"Int J Technol Assess Health Care"},{"key":"579_CR8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.msard.2015.08.004","volume":"4","author":"Pereira ABCN Gama da","year":"2015","unstructured":"da Gama Pereira ABCN, Lacativa MCS, da Costa Pereira FFC, Alvarenga RMP. Prevalence of multiple sclerosis in Brazil: a systematic review. Mult Scler Relat Disord. 2015;4:572\u20139.","journal-title":"Mult Scler Relat Disord"},{"key":"579_CR9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502\u201317.","journal-title":"Lancet"},{"key":"579_CR10","first-page":"2611","volume-title":"Harrison\u2019s principles of internal medicine","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Goodwin DS. Multiple sclerosis and other demyelinating diseases. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, editors. Harrison\u2019s principles of internal medicine. 17th ed. New York: McGraw-Hill Medical; 2008. p. 2611\u201321.","edition":"17"},{"key":"579_CR11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrneurol.2015.49","volume":"11","author":"RM Ransohoff","year":"2015","unstructured":"Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis\u2014a quiet revolution. Nat Rev Neurol. 2015;11:246\u2013246.","journal-title":"Nat Rev Neurol."},{"key":"579_CR12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/brain\/116.1.117","volume":"116","author":"B Runmarker","year":"1993","unstructured":"Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116:117\u201334.","journal-title":"Brain"},{"key":"579_CR13","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","volume":"343","author":"C Confavreux","year":"2000","unstructured":"Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430\u20138.","journal-title":"N Engl J Med"},{"issue":"Pt 1","key":"579_CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","volume":"112","author":"BG Weinshenker","year":"1989","unstructured":"Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133\u201346.","journal-title":"Brain."},{"key":"579_CR15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278\u201386.","journal-title":"Neurology."},{"key":"579_CR16","first-page":"175","volume":"37","author":"MM Goldenberg","year":"2012","unstructured":"Goldenberg MM. Multiple sclerosis review. P T. 2012;37:175\u201384.","journal-title":"P T"},{"key":"579_CR17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254\u201360.","journal-title":"Lancet Neurol."},{"key":"579_CR18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13311-015-0412-4","volume":"13","author":"J Ingwersen","year":"2016","unstructured":"Ingwersen J, Aktas O, Hartung H-P. Advances in and algorithms for the treatment of relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016;13:47\u201357.","journal-title":"Neurotherapeutics."},{"key":"579_CR19","first-page":"448","volume":"8","author":"L Radick","year":"2015","unstructured":"Radick L, Mehr SR. The latest innovations in the drug pipeline for multiple sclerosis. Am Health Drug Benefits. 2015;8:448\u201353.","journal-title":"Am Health Drug Benefits."},{"key":"579_CR20","unstructured":"Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade, Minist\u00e9rio da Sa\u00fade, Rep\u00fablica Federativa do Brasil. Portaria n\u00b0 97, de 22 de mar\u00e7o de 2001. Di\u00e1rio Oficial da Uni\u00e3o. Bras\u00edlia, DF: Imprensa Nacional; 2001. p. 114."},{"key":"579_CR21","unstructured":"Secretaria de Aten\u00e7\u00e3o \u00e0 Sa\u00fade, Minist\u00e9rio da Sa\u00fade, Rep\u00fablica Federativa do Brasil. Portaria no 391, de 5 de maio de 2015. Di\u00e1rio Oficial da Uni\u00e3o. Bras\u00edlia, DF: Imprensa Nacional; 2015. p. 40."},{"issue":"9357","key":"579_CR22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(03)12512-3","volume":"361","author":"G Filippini","year":"2003","unstructured":"Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D\u2019Amico R, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361(9357):545\u201352.","journal-title":"Lancet"},{"key":"579_CR23","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","volume":"7","author":"DD Mikol","year":"2008","unstructured":"Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903\u201314.","journal-title":"Lancet Neurol."},{"key":"579_CR24","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","volume":"8","author":"P O\u2019Connor","year":"2009","unstructured":"O\u2019Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20\u00a0mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889\u201397.","journal-title":"Lancet Neurol."},{"key":"579_CR25","doi-asserted-by":"publisher","unstructured":"Tramacere I, Del Giovane C, Salanti G, D\u2019Amico R, Filippini G. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015;9:CD011381. https:\/\/doi.org\/10.1002\/14651858.CD011381.pub2 .","DOI":"10.1002\/14651858.CD011381.pub2"},{"key":"579_CR26","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ Br Med J Publ Group. 2011;343:d5928.","journal-title":"BMJ Br Med J Publ Group"},{"key":"579_CR27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14:429\u201337.","journal-title":"Value Health."},{"key":"579_CR28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","volume":"43","author":"The IFNB Multiple Sclerosis Study Group","year":"1993","unstructured":"The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655\u2013655.","journal-title":"Neurology."},{"key":"579_CR29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285\u201394.","journal-title":"Ann Neurol"},{"key":"579_CR30","doi-asserted-by":"crossref","unstructured":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498\u2013504.","DOI":"10.1016\/S0140-6736(98)03334-0"},{"key":"579_CR31","first-page":"349","volume":"7","author":"OA Khan","year":"2001","unstructured":"Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing\u2013remitting multiple sclerosis: results after 18\u00a0months of therapy. Mult Scler. 2001;7:349\u201353.","journal-title":"Mult Scler."},{"key":"579_CR32","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(02)08430-1","volume":"359","author":"L Durelli","year":"2002","unstructured":"Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453\u201360.","journal-title":"Lancet"},{"key":"579_CR33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/01.wnl.0000204018.52311.ec","volume":"66","author":"N Koch-Henriksen","year":"2006","unstructured":"Koch-Henriksen N, S\u00f8rensen PS, Christensen T, Frederiksen J, Ravnborg M, Jensen K, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology. 2006;66:1056\u201360.","journal-title":"Neurology."},{"key":"579_CR34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1600-0404.2006.00585.x","volume":"113","author":"M Etemadifar","year":"2006","unstructured":"Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2006;113:283\u20137.","journal-title":"Acta Neurol Scand"},{"key":"579_CR35","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.clinthera.2007.09.025","volume":"29","author":"SR Schwid","year":"2007","unstructured":"Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29:2031\u201348.","journal-title":"Clin Ther"},{"key":"579_CR36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.23863","volume":"73","author":"FD Lublin","year":"2013","unstructured":"Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73:327\u201340.","journal-title":"Ann Neurol"},{"key":"579_CR37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40258-013-0073-6","volume":"12","author":"AL Caires Souza de","year":"2014","unstructured":"de Caires Souza AL, de Souza ALC, de Assis Acurcio F, J\u00fanior AAG, do Nascimento RCRM, Godman B, et al. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review. Appl Health Econ Health Policy. 2014;12:19\u201332.","journal-title":"Appl Health Econ Health Policy"},{"key":"579_CR38","unstructured":"Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos, Minist\u00e9rio da Sa\u00fade, Rep\u00fablica Federativa do Brasil. Portaria no 27, de 6 de julho de 2016. Di\u00e1rio Oficial da Uni\u00e3o. Bras\u00edlia, DF: Imprensa Nacional; 2016. p. 35."},{"key":"579_CR39","unstructured":"Drugs@FDA: FDA approved drug products. http:\/\/www.fda.gov\/drugsatfda . Accessed 16 May 2017."},{"key":"579_CR40","unstructured":"Consulta a produtos registrados - Anvisa [Internet]. http:\/\/portal.anvisa.gov.br\/consulta-produtos-registrados . Accessed 16 May 2017."},{"key":"579_CR41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/S0266462312000372","volume":"28","author":"C Henshall","year":"2012","unstructured":"Henshall C, Schuller T, Mardhani-Bayne L. Using health technology assessment to support optimal use of technologies in current practice: the challenge of \u201cdisinvestment\u201d. Int J Technol Assess Health Care. 2012;28:203\u201310.","journal-title":"Int J Technol Assess Health Care"},{"key":"579_CR42","unstructured":"CADTH. Canadian Agency for Drugs and Technologies in Health. Comparative clinical and cost-effectiveness of drug therapies for relapsing-remitting multiple sclerosis. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/TR0004_RRMS_ScienceReport_e.pdf . Accessed 23 May 2017."},{"key":"579_CR43","unstructured":"NICE. Technology appraisal guidance 32. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. 2002. https:\/\/www.nice.org.uk\/Guidance\/TA32 . Accessed 24 May 2017."},{"key":"579_CR44","doi-asserted-by":"crossref","first-page":"b4677","DOI":"10.1136\/bmj.b4677","volume":"339","author":"M Boggild","year":"2009","unstructured":"Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T, Dobson C, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ. 2009;339:b4677.","journal-title":"BMJ"},{"key":"579_CR45","doi-asserted-by":"crossref","first-page":"c1672","DOI":"10.1136\/bmj.c1672","volume":"340","author":"J Raftery","year":"2010","unstructured":"Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ. 2010;340:c1672.","journal-title":"BMJ"},{"issue":"5","key":"579_CR46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1474-4422(15)00018-6","volume":"14","author":"J Palace","year":"2015","unstructured":"Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6\u00a0years: a clinical cohort study with natural history comparator. Lancet Neurol. 2015;14(5):497\u2013505.","journal-title":"Lancet Neurol"},{"key":"579_CR47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13:657\u201365.","journal-title":"Lancet Neurol."},{"key":"579_CR48","unstructured":"Top multiple sclerosis drugs worldwide by revenue 2013 | Statistic [Internet]. Statista. [cited 2017 May 5]. https:\/\/www.statista.com\/statistics\/372273\/leading-ten-ms-medications-by-revenue\/ . Accessed 31 May 2017."},{"key":"579_CR49","unstructured":"Aitken M, Kleinrock M, Pennente K, Lyle J, Nass D, Caskey L. Medicines use and spending in the U.S. A review of 2015 and outlook to 2020 [Internet]. IMS Institute for Healthcare Informatics; 2016. http:\/\/www.imshealth.com\/en\/thought-leadership\/quintilesims-institute\/reports\/medicines-use-and-spending-in-the-us-a-review-of-2015-and-outlook-to-2020 . Accessed 31 May 2017."},{"key":"579_CR50","unstructured":"Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos, Minist\u00e9rio da Sa\u00fade, Rep\u00fablica Federativa do Brasil. Portaria no 19, de 19 de abril de 2017. Di\u00e1rio Oficial da Uni\u00e3o. Bras\u00edlia, DF: Imprensa Nacional; 2017. p. 58."},{"key":"579_CR51","unstructured":"Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos, Minist\u00e9rio da Sa\u00fade, Rep\u00fablica Federativa do Brasil. Portaria no 14, de 13 de mar\u00e7o de 2017. Di\u00e1rio Oficial da Uni\u00e3o. Bras\u00edlia, DF: Imprensa Nacional; 2017. p. 53."},{"key":"579_CR52","unstructured":"FIOCRUZ. Technology transfer beta interferons. https:\/\/agencia.fiocruz.br\/assinado-acordo-para-transfer%C3%AAncia-de-tecnologia-do-betainterferona-1a . Accessed 5 Apr 2017."},{"issue":"5","key":"579_CR53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00019053-200927050-00010","volume":"27","author":"B Godman","year":"2009","unstructured":"Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics. 2009;27(5):435\u20138.","journal-title":"Pharmacoeconomics."},{"issue":"6","key":"579_CR54","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40258-013-0059-4","volume":"11","author":"U Hesse","year":"2013","unstructured":"Hesse U, Godman B, Petzold M, Martin A, Malmstrom RE. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries. Appl Health Econ Health Policy. 2013;11(6):677\u201385.","journal-title":"Appl Health Econ Health Policy."},{"issue":"1","key":"579_CR55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2217\/cer.13.83","volume":"3","author":"A Martin","year":"2014","unstructured":"Martin A, Godman B, Miranda J, Tilstone J, Saleem N, Olsson E, et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. J Comp Effect Res. 2014;3(1):41\u201351.","journal-title":"J Comp Effect Res."},{"issue":"4","key":"579_CR56","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2007.02907.x","volume":"64","author":"S Sakshaug","year":"2007","unstructured":"Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol. 2007;64(4):476\u201381.","journal-title":"Br J Clin Pharmacol"},{"key":"579_CR57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1257\/jep.29.1.139","volume":"29","author":"DH Howard","year":"2015","unstructured":"Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139\u201362.","journal-title":"J Econ Perspect"},{"key":"579_CR58","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.mayocp.2015.06.001","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90:996\u20131000.","journal-title":"Mayo Clin Proc"},{"key":"579_CR59","unstructured":"Ghinea N, Kerridge I, Lipworth W. If we don\u2019t talk about value, cancer drugs will become terminal for health systems [Internet]. The Conversation. 2015. http:\/\/theconversation.com\/if-we-dont-talk-about-value-cancer-drugs-will-become-terminal-for-health-systems-44072 . Accessed 15 May 2017."},{"key":"579_CR60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1586\/17512433.2015.990380","volume":"8","author":"B Godman","year":"2015","unstructured":"Godman B, Malmstr\u00f6m RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8:77\u201394.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"579_CR61","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Ci\u00eancia, Tecnologia e Insumos Estrat\u00e9gicos. Departamento de Gest\u00e3o e Incorpora\u00e7\u00e3o de Tecnologias em Sa\u00fade. Methodological Guidelines: Health Technology Performance Assessment. Bras\u00edlia, DF: Minist\u00e9rio da Sa\u00fade do Brasil"},{"key":"579_CR62","doi-asserted-by":"crossref","unstructured":"Malmstr\u00f6m RE, Godman BB, Diogene E, Baumg\u00e4rtel C, Bennie M, Bishop I, et al. Dabigatran\u2014a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:1\u201331.","DOI":"10.3389\/fphar.2013.00039"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-017-0579-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T23:29:08Z","timestamp":1570318148000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-017-0579-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1007\/s40273-017-0579-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]}}}